What are the indications, dosing regimens, contraindications, and common adverse effects of octreotide (synthetic somatostatin analogue)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Octreotide: Clinical Overview

Primary Indications

Octreotide is FDA-approved for three specific conditions: acromegaly (in patients with inadequate response to surgery, radiation, or bromocriptine), symptomatic treatment of metastatic carcinoid tumors (for diarrhea and flushing), and VIPomas (for profuse watery diarrhea). 1

Approved Indications

  • Acromegaly: Reduces growth hormone (GH) and IGF-1 levels in patients who have failed or cannot undergo surgery, pituitary irradiation, or maximally tolerated bromocriptine 1
  • Carcinoid tumors: Controls severe diarrhea and flushing episodes in metastatic disease 2, 1
  • VIPomas: Treats profuse watery diarrhea associated with VIP-secreting tumors 2, 3, 1

Additional Clinical Uses (Based on Guidelines)

  • Glucagonomas: Improves necrolytic migratory erythema and other symptoms 3
  • Carcinoid crisis prevention: Critical perioperative use in functional NETs 2, 3
  • Dumping syndrome: Effective for both early and late symptoms post-gastric surgery 4

Limited or Ineffective Uses

  • Gastrinomas: NOT first-line; PPIs are preferred. Use only in refractory cases 2
  • Insulinomas: Often ineffective (only 50-60% have appropriate somatostatin receptors). Diazoxide is preferred at 200-600 mg/day orally 2

Dosing Regimens

Short-Acting Octreotide (Subcutaneous)

For acute symptom control and initial stabilization, start with short-acting octreotide 50-100 mcg subcutaneously 2-3 times daily, with maximum doses up to 1500 mcg/day. 3, 1

  • Acromegaly: 50 mcg three times daily initially; titrate based on GH/IGF-1 levels every 2 weeks. Most patients require 100 mcg three times daily; maximum 500 mcg three times daily 1
  • Carcinoid tumors: 100-600 mcg/day in 2-4 divided doses initially (mean 300 mcg/day); maintenance median ~450 mcg/day 1
  • VIPomas: 200-300 mcg/day in 2-4 divided doses initially 1
  • Carcinoid crisis prevention: 50 mcg/hour IV starting 12 hours before procedure, continuing during and 48 hours after 3
  • Dumping syndrome: 50-100 mcg subcutaneously before meals 4

Long-Acting Formulations (Standard of Care)

Long-acting formulations should be considered the standard of care for chronic symptomatic treatment due to superior quality of life and comparable or better efficacy. 2

  • Octreotide LAR: 10,20, or 30 mg intramuscularly every 4 weeks 2
  • Lanreotide Autogel: 60,90, or 120 mg every 4 weeks 2
  • Start with lower doses and up-titrate to achieve stabilization 2
  • Therapeutic levels not achieved for 10-14 days after LAR injection 5
  • For breakthrough symptoms: Add short-acting octreotide 2-3 times daily (max ~1 mg/day) OR reduce injection interval from 4 to 3 weeks 2

Transition Strategy

Stabilize patients on short-acting octreotide for 10-28 days before converting to long-acting formulations 3

Contraindications

The only absolute contraindication is hypersensitivity to octreotide or any component of the formulation. 1

Warnings and Precautions

Cardiac Function Abnormalities

Complete atrioventricular block has been reported with IV octreotide, particularly at higher than recommended doses or with continuous infusion. 1

  • Bradycardia occurred in 25% of acromegalic patients 1
  • Conduction abnormalities in 10%, arrhythmias in 9% 1
  • Consider cardiac monitoring for IV administration 1
  • Dose adjustments of beta-blockers and other bradycardia-inducing drugs may be necessary 1

Cholelithiasis

Gallbladder abnormalities occur in approximately 63% of patients on long-term therapy (27% gallstones, 24% sludge, 12% biliary duct dilatation). 1

  • Incidence reaches 52% in patients treated ≥12 months 1
  • Less than 2% develop stones with treatment <1 month 1
  • Acute cholecystitis, ascending cholangitis, biliary obstruction, cholestatic hepatitis, or pancreatitis can occur 1
  • Discontinue if complications suspected 1
  • Monitor periodically with ultrasound if clinically indicated

Glucose Metabolism

Octreotide alters the balance between insulin, glucagon, and GH, potentially causing hypoglycemia or hyperglycemia. 1

  • Hypoglycemia occurred in 3% of acromegalic patients 1
  • Hyperglycemia occurred in 16% of acromegalic patients 1
  • Post-prandial hyperglycemia with impaired insulin secretion is common 6
  • Monitor glucose levels and adjust anti-diabetic medications as needed 1
  • One patient in studies required oral hypoglycemic agents 6

Thyroid Function

Hypothyroidism may occur; monitor thyroid function periodically. 1

  • Assess total and/or free T4 at baseline and during chronic therapy 1

Common Adverse Effects

Most Frequent (>10% incidence)

In acromegalic patients 1:

  • Gallbladder abnormalities
  • Sinus bradycardia
  • Diarrhea/loose stools
  • Nausea
  • Abdominal discomfort
  • Hyperglycemia
  • Hypothyroidism

Other Common Side Effects

Generally mild and well-tolerated 3:

  • Pain or burning at injection site
  • Fat malabsorption
  • Vitamin A and D malabsorption
  • Headaches
  • Dizziness
  • Flatulence, abdominal cramps (usually abate with continued treatment) 7
  • Reversible hair loss (rarely alopecia) 7

Monitoring Requirements

Acromegaly

  • GH or IGF-1 levels every 2 weeks after initiation or dose change 1
  • Goal: GH <5 ng/mL or IGF-1 within normal range 1
  • Withdraw octreotide yearly for ~4 weeks to assess disease activity 1

Carcinoid Tumors

  • Urinary 5-HIAA, plasma serotonin, plasma Substance P 1
  • Echocardiogram if signs/symptoms of carcinoid heart disease 5

VIPomas

  • Plasma VIP levels 1

All Patients

  • Circulating and urinary hormone levels during treatment 3
  • Regular imaging as clinically indicated 3
  • Glucose monitoring 1
  • Thyroid function tests 1

Drug Interactions

Monitor and adjust doses of the following when used with octreotide 1:

  • Cyclosporine (may interfere with absorption) 8
  • Insulin and oral hypoglycemic agents
  • Beta-blockers
  • Bromocriptine

Lutetium Lu 177 Dotatate: Discontinue octreotide at least 24 hours prior to each dose 1

Efficacy Data

Neuroendocrine Tumors

  • Biochemical response (hormone inhibition): 30-70% of patients 2, 3, 2
  • Symptomatic control: Majority of patients 2
  • Tumor shrinkage >50%: 59% of patients 2
  • Median time to tumor progression in PROMID trial: 14.3 months vs 6 months with placebo (p=0.000072) 5

Specific Syndromes

  • Carcinoid syndrome: Substantial relief of flushing and diarrhea in majority 3
  • VIPomas: Dramatic response with cessation of diarrhea in this life-threatening syndrome 3
  • Dumping syndrome: 73% response in case series, 64% in RCTs 9

Special Considerations

Imaging Interactions

  • Withdraw short-acting octreotide 24-48 hours before somatostatin receptor scintigraphy 2
  • For long-acting formulations, schedule imaging toward end of dosing interval, just before next injection 2

Reproductive Potential

Advise premenopausal females of potential for unintended pregnancy 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.